Jiangsu Jibeier Pharmaceutical (SH:688566)2024-05-10 10:08Group 1: Financial Performance and Dividend Policy - The company decided not to distribute profits for the 2023 fiscal year due to ongoing stock issuance procedures, which includes no cash dividends, no bonus shares, and no capital reserve transfers [2][3] - The board has proposed to authorize the board to formulate a specific plan for the 2024 interim dividend, which will be reviewed at the 2023 annual shareholders' meeting [4] Group 2: Product Development and Clinical Trials - The company has developed a new diabetes drug, JJH202301, which has shown promising results in preliminary pharmacokinetic tests, significantly extending the drug's half-life and reducing metabolite production [2] - The anti-cancer drug JJH201601 has received approval for clinical trials in advanced solid tumors and is currently in Phase I clinical research [3][5] - The company has patented multiple formulations of the drug Likujun, enhancing its market protection and ensuring product quality [3] Group 3: Market Potential and Sales Growth - The overall market for white blood cell-boosting drugs is substantial, with significant growth potential for Likujun, which is the leading product in this category [5] - Sales data indicates uneven development across different regions, suggesting a large untapped market nationally [5] - The company is actively promoting Likujun in oncology and other key areas, contributing to sustained growth in operating performance [4]